Category: elafibranor

  • Ipsen places €480m bet on Genfit’s liver drug elafibranor

    Genfit was hit hard last year when it abandoned a phase 3 programme for elafibranor in non-alcoholic steatohepatitis (NASH), but pledged to press on with the drug in other indications – and now has the help of fellow French pharma group Ipsen. Ipsen has taken rights to PPAR agonist elafibranor as a treatment for primary […]